Literature DB >> 28442580

Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone.

Joanna C Jacob1, Justin L Poklis1, Hamid I Akbarali1, Graeme Henderson1, William L Dewey2.   

Abstract

This study compared the development of tolerance to two orally bioavailable prescription opioids, oxycodone and hydrocodone, to that of morphine, and the reversal of this tolerance by ethanol. Oxycodone (s.c.) was significantly more potent in the mouse tail-withdrawal assay than either morphine or hydrocodone. Oxycodone was also significantly more potent in this assay than hydrocodone when administered orally. Tolerance was seen following chronic subcutaneous administration of each of the three drugs and by the chronic administration of oral oxycodone, but not following the chronic oral administration of hydrocodone. Ethanol (1 g/kg i.p.) significantly reversed the tolerance to the subcutaneous administration of each of the three opioids that developed when given 30 minutes prior to challenge doses. It took twice as much ethanol, when given orally, to reverse the tolerance to oxycodone. We investigated whether the observed tolerance to oxycodone and its reversal by ethanol were due to biodispositional changes or reflected a true neuronal tolerance. As expected, a relationship between brain oxycodone concentrations and activity in the tail-immersion test existed following administration of acute oral oxycodone. Following chronic treatment, brain oxycodone concentrations were significantly lower than acute concentrations. Oral ethanol (2 g/kg) reversed the tolerance to chronic oxycodone, but did not alter brain concentrations of either acute or chronic oxycodone. These studies show that there is a metabolic component of tolerance to oxycodone; however, the reversal of that tolerance by ethanol is not due to an alteration of the biodisposition of oxycodone, but rather is neuronal in nature.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28442580      PMCID: PMC5454589          DOI: 10.1124/jpet.117.241083

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  29 in total

1.  Relationship of brain morphine levels to analgesic activity in acutely treated mice and rats and in pellet implanted mice.

Authors:  G A Patrick; W L Dewey; T C Spaulding; L S Harris
Journal:  J Pharmacol Exp Ther       Date:  1975-06       Impact factor: 4.030

2.  Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users.

Authors:  Thomas Kerr; Nadia Fairbairn; Mark Tyndall; David Marsh; Kathy Li; Julio Montaner; Evan Wood
Journal:  Drug Alcohol Depend       Date:  2006-09-07       Impact factor: 4.492

3.  Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

Authors:  U Mayer; E Wagenaar; B Dorobek; J H Beijnen; P Borst; A H Schinkel
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

4.  Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats.

Authors:  Hazem E Hassan; Alan L Myers; Insong J Lee; Andrew Coop; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2007-09       Impact factor: 3.534

5.  The synergistic analgesic interactions between hydrocodone and ibuprofen.

Authors:  Yuri A Kolesnikov; Roger S Wilson; Gavril W Pasternak
Journal:  Anesth Analg       Date:  2003-12       Impact factor: 5.108

6.  Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain.

Authors:  Carsten K Nielsen; Fraser B Ross; Shahrdad Lotfipour; Kamal S Saini; Stephen R Edwards; Maree T Smith
Journal:  Pain       Date:  2007-04-30       Impact factor: 6.961

7.  Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys.

Authors:  Patrick M Beardsley; Mario D Aceto; Charles D Cook; Edward R Bowman; Jennifer L Newman; Louis S Harris
Journal:  Exp Clin Psychopharmacol       Date:  2004-08       Impact factor: 3.157

8.  Free oxycodone concentrations in 67 postmortem cases from the Hennepin County medical examiner's office.

Authors:  Jonathan G Thompson; Steve Vanderwerf; Justin Seningen; Mary Carr; Julie Kloss; Fred S Apple
Journal:  J Anal Toxicol       Date:  2008-10       Impact factor: 3.367

9.  Effect of Tamoxifen and Brain-Penetrant Protein Kinase C and c-Jun N-Terminal Kinase Inhibitors on Tolerance to Opioid-Induced Respiratory Depression in Mice.

Authors:  Sarah L Withey; Rob Hill; Abigail Lyndon; William L Dewey; Eamonn Kelly; Graeme Henderson
Journal:  J Pharmacol Exp Ther       Date:  2017-01-27       Impact factor: 4.030

10.  Reversal of morphine analgesic tolerance by ethanol in the mouse.

Authors:  L C Hull; B H Gabra; C P Bailey; G Henderson; W L Dewey
Journal:  J Pharmacol Exp Ther       Date:  2013-03-25       Impact factor: 4.030

View more
  8 in total

1.  Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition.

Authors:  Rob Hill; William L Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2018-05-07       Impact factor: 8.739

2.  Ethanol Reversal of Oxycodone Tolerance in Dorsal Root Ganglia Neurons.

Authors:  Joanna C Jacob; Kensuke Sakakibara; Ryan A Mischel; Graeme Henderson; William L Dewey; Hamid I Akbarali
Journal:  Mol Pharmacol       Date:  2018-02-21       Impact factor: 4.436

Review 3.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

4.  Role of Efficacy as a Determinant of Locomotor Activation by Mu Opioid Receptor Ligands in Female and Male Mice.

Authors:  Edna J Santos; Matthew L Banks; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2022-04-30       Impact factor: 4.402

5.  Role of Acetaldehyde in Ethanol Reversal of Tolerance to Morphine-Induced Respiratory Depression in Mice.

Authors:  Rob Hill; Alexandra Conibear; William Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Adv Drug Alcohol Res       Date:  2022-01-31

6.  Concurrent Assessment of the Antinociceptive and Behaviorally Disruptive Effects of Opioids in Squirrel Monkeys.

Authors:  Sarah L Withey; Carol A Paronis; Jack Bergman
Journal:  J Pain       Date:  2018-03-02       Impact factor: 5.820

7.  Maternal Opioid Exposure Culminates in Perturbed Murine Neurodevelopment and Hyperactive Phenotype in Adolescence.

Authors:  Caitlin R Schlagal; Tiffany J Dunn; Pei Xu; Daniel E Felsing; Christina R Merritt; Sanjana Manja; Robert G Fox; Shelly A Buffington; George Saade; Kelly T Dineley; Yongjia Yu; Kathryn A Cunningham; Ping Wu
Journal:  Neuroscience       Date:  2021-03-31       Impact factor: 3.708

8.  Research Needs for Inpatient Management of Severe Alcohol Withdrawal Syndrome: An Official American Thoracic Society Research Statement.

Authors:  Tessa L Steel; Majid Afshar; Scott Edwards; Sarah E Jolley; Christine Timko; Brendan J Clark; Ivor S Douglas; Amy L Dzierba; Hayley B Gershengorn; Nicholas W Gilpin; Dwayne W Godwin; Catherine L Hough; José R Maldonado; Anuj B Mehta; Lewis S Nelson; Mayur B Patel; Darius A Rastegar; Joanna L Stollings; Boris Tabakoff; Judith A Tate; Adrian Wong; Ellen L Burnham
Journal:  Am J Respir Crit Care Med       Date:  2021-10-01       Impact factor: 21.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.